Shanghai Junshi Biosciences Management
Management criteria checks 3/4
Shanghai Junshi Biosciences' CEO is Cong Li, appointed in Nov 2021, has a tenure of 3.08 years. total yearly compensation is CN¥4.22M, comprised of 100% salary and 0% bonuses, including company stock and options. directly owns 0.013% of the company’s shares, worth HK$3.30M. The average tenure of the management team and the board of directors is 3.3 years and 5.5 years respectively.
Key information
Cong Li
Chief executive officer
CN¥4.2m
Total compensation
| CEO salary percentage | 100.0% |
| CEO tenure | 3.1yrs |
| CEO ownership | 0.01% |
| Management average tenure | 3.3yrs |
| Board average tenure | 5.5yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -CN¥2b |
| Jun 30 2024 | n/a | n/a | -CN¥2b |
| Mar 31 2024 | n/a | n/a | -CN¥2b |
| Dec 31 2023 | CN¥4m | CN¥4m | -CN¥2b |
| Sep 30 2023 | n/a | n/a | -CN¥2b |
| Jun 30 2023 | n/a | n/a | -CN¥2b |
| Mar 31 2023 | n/a | n/a | -CN¥3b |
| Dec 31 2022 | CN¥4m | CN¥4m | -CN¥2b |
Compensation vs Market: Cong's total compensation ($USD578.78K) is about average for companies of similar size in the Hong Kong market ($USD482.25K).
Compensation vs Earnings: Cong's compensation has increased whilst the company is unprofitable.
CEO
Cong Li (60 yo)
3.1yrs
Tenure
CN¥4,224,000
Compensation
Mr. Cong Li has been Co-Chief Executive Officer and Executive Director at Shanghai Junshi Biosciences Co., Ltd. since November 2, 2021 and served as Non-Executive Director since December 22, 2016 until Nov...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman | 9.8yrs | CN¥8.50m | 13.09% HK$ 3.3b | |
| Co-CEO & Executive Director | 3.1yrs | CN¥4.22m | 0.013% HK$ 3.3m | |
| GM, CEO & Executive Director | less than a year | CN¥5.86m | no data | |
| Executive Vice-Chairman of the Board | 6.5yrs | CN¥9.93m | 0.0051% HK$ 1.3m | |
| Financial Director | 4.1yrs | CN¥2.73m | 0.00071% HK$ 181.4k | |
| Deputy GM & Executive Director | no data | CN¥8.13m | 0.88% HK$ 224.3m | |
| Senior VP & Executive Director | no data | CN¥8.01m | no data | |
| Deputy GM | 5.3yrs | CN¥1.32m | 0.0010% HK$ 260.6k | |
| Senior VP of Government Affairs & Executive Director | less than a year | no data | 0.0096% HK$ 2.5m | |
| Assistant to GM & Chief of Internal Audit Department | 4.1yrs | no data | no data | |
| Chief Commercial Officer | 3.4yrs | no data | no data | |
| Chief Medical Officer | no data | no data | no data |
3.3yrs
Average Tenure
51.5yo
Average Age
Experienced Management: 1877's management team is considered experienced (3.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman | 9.8yrs | CN¥8.50m | 13.09% HK$ 3.3b | |
| Co-CEO & Executive Director | 8yrs | CN¥4.22m | 0.013% HK$ 3.3m | |
| GM, CEO & Executive Director | 2.5yrs | CN¥5.86m | no data | |
| Executive Vice-Chairman of the Board | 6.5yrs | CN¥9.93m | 0.0051% HK$ 1.3m | |
| Deputy GM & Executive Director | 8yrs | CN¥8.13m | 0.88% HK$ 224.3m | |
| Senior VP & Executive Director | 8yrs | CN¥8.01m | no data | |
| Deputy GM | 1.2yrs | CN¥1.32m | 0.0010% HK$ 260.6k | |
| Senior VP of Government Affairs & Executive Director | 1.2yrs | no data | 0.0096% HK$ 2.5m | |
| Non-Executive Director | 9.6yrs | no data | 0.79% HK$ 201.7m | |
| Independent Non-Executive Director | 4.5yrs | CN¥200.00k | no data | |
| Independent Non-Executive Director | 3yrs | CN¥200.00k | no data | |
| Chairman of the Board of Supervisors | less than a year | no data | no data |
5.5yrs
Average Tenure
57yo
Average Age
Experienced Board: 1877's board of directors are considered experienced (5.5 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/25 11:01 |
| End of Day Share Price | 2024/12/24 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Shanghai Junshi Biosciences Co., Ltd. is covered by 19 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Congmin Yuan | Citic Securities Co., Ltd. |
| Tan Huan Gan | Citic Securities Co., Ltd. |
| Muk Tsz Yung | Citigroup Inc |